Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Gold Price Ends Lower for Fourth Week Despite Rebound as Fed Rate Hike Bets Strengthen 
Wall Street Ends Mixed as Micron Surges, Apple Drops After Price Hikes 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
South Korea’s KOSPI Jumps Over 5% as Samsung, SK Hynix Rally on Micron Earnings Boost 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
US Dollar Slips After PCE Inflation Data as Fed Rate Hike Expectations Stay Elevated 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
The four types of dementia most people don’t know exist 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Researchers from the Korea Advanced Institute of Science and Technology (KAIST) have developed a wearable green organic light-emitting diode (OLED) with a 470-nanometer (nm) wavelength that can cure jaundice in infants.
The OLED provides sufficient power for jaundice treatment even at low voltage, durability for over 100 hours of operation, a low operating temperature of less than 35 Celsius degrees, and flexibility that can endure over 1,000 bends at a 2 mm radius of curvature.
The bilirubin level of the infants’ serum reaches 12 milligrams per decilitre (mg/dL) within three hours of being exposed to the OLED, indicating the completed treatment of jaundice.
Unlike existing light-emitting diode (LED)-based jaundice treatment devices currently used at hospitals, the OLED showed uniform and effective treatment functions.
